Skip to content

An ‘Ozempic baby boom’? The GLP-1 pregnancy plot twist

Short Wave

Hosted by Emily Kwong

12m
Transcript

Original podcast

Where to listen

Summary

Written by a model from the transcript; not yet reviewed.

This episode of Short Wave examines the unexpected intersection of GLP-1 weight loss drugs like Ozempic, Mounjaro, and Zepbound with pregnancy and reproductive health. Host Emily Kwong and OB-GYN Amy Valent discuss the viral social media phenomenon of unexpected pregnancies among people taking these medications, known as the Ozempic baby boom. They explain how certain GLP-1 medications can decrease the efficacy of oral contraceptives due to altered intestinal absorption, leading to recommendations for barrier methods or non-oral contraceptives like IUDs. The conversation also covers the benefits of GLP-1s for patients with conditions like polyendocrine metabolic ovarian syndrome and diabetes, as well as new guidance from the American College of Obstetricians and Gynecologists advising patients to stop taking the drugs one to two months before attempting to get pregnant.

  • Some GLP-1 medications like tirdepatide can decrease the efficacy of oral contraceptives. 5:15
  • GLP-1s can help optimize metabolic systems and help ovaries wake up in patients with polyendocrine metabolic ovarian syndrome. 7:26
  • Patients should stop taking GLP-1 medications one to two months before trying to become pregnant. 9:25

Chapters

  1. 0:00
    Episode Introduction and Sponsor Ads

    Hosts introduce the episode and play sponsor messages before diving into the topic.

  2. 0:36
    Amy Valentin’s Front‑Line Experience

    Amy Valentin, an OB‑GYN, shares her observations of GLP‑1 drug use and the emerging “Ozempic baby” phenomenon.

  3. 1:11
    Social Media Buzz and the Ozempic Baby Boom

    The hosts discuss the viral stories of unplanned pregnancies linked to GLP‑1 drugs and the confusion it caused.

  4. 2:02
    Clinical Guidance from ACOG

    ACOG’s new guidelines are introduced, outlining how OB‑GYNs should counsel patients about GLP‑1 use and pregnancy.

Highlights

  • 5:15

    Contraceptive Efficacy Concernsinsight

    The guest explains that tirsepatide has been shown to decrease the efficacy of oral contraceptives, prompting recommendations to use barrier methods or non-oral options.

  • 7:26

    Benefits for PCOS Patientsinsight

    GLP-1s can help optimize metabolic systems in patients with polyendocrine metabolic ovarian syndrome, helping their ovaries wake up and start ovulating again.

  • 8:00

    Lowering Blood Sugar Before Pregnancydata

    Using GLP-1s to lower blood sugars prior to pregnancy is a game changer because elevated blood sugars increase the risk of birth defects and miscarriages.

  • 9:25

    Discontinuation Timelinestrategy

    The guest advises that patients should stop taking GLP-1 medications one to two months before pregnancy, depending on the half-life of the specific drug.

  • 10:47

    Nutritional Risks During Pregnancyinsight

    Because GLP-1s eliminate food noise and reduce food intake, they can cause a lack of essential nutrients needed to grow and develop a healthy baby.

  • 12:40

    Pregnancy as a Scientific Afterthoughtdebate

    The discussion highlights how pregnancy is often excluded from the initial development of wonderful therapeutics, leaving researchers to study real-world effects later.

Quotes

  • “We have so many people that this affects. It is actually like so good that we have some guidance to help us.”
    Unnamed speaker · 2:24
  • “I think most people that are on a GLP-1, they'll say, oh, it's stopping kind of like the food noise.”
    Unnamed speaker · 10:47
  • “So there's so many different populations that having the effects of these medications are benefiting so much.”
    Unnamed speaker · 8:39
  • “The main one is that people who are pregnant should definitely stop taking these drugs. And they should stop taking them before pregnancy.”
    Emily Kwong · 9:12
  • “GLP-1s can be really beneficial in this population, that can help optimize those systems in a way that they can start to ovulate again, their ovaries start to wake up.”
    Unnamed speaker · 7:26
  • Vuori 0:00–0:16
  • Whole Foods Market 3:03–3:28
  • Schwab 3:29–3:45
  • Mint Mobile 3:45–4:15
  • Bowlin Branch 13:49–14:14
  • Mint Mobile 14:15–14:44

About this episode

The explosion of GLP-1 drugs has created a gray zone for pregnancy. That recently prompted the American College of Obstetricians and Gynecologists to issue its first ever guidance https://www.acog.org/clinical/guidance/practice-advisory/2026/10/use-of-glucagon-like-peptide-1-receptor-agonists-in-pregnancy-and-lactation/ on the topic. In a twist, the drugs may boost fertility for some, leading to more pregnancies – a phenomenon known on social media as “Ozempic babies”. But doctors caution against using the drugs during pregnancy itself. In fact, the more we looked into this story, the more twists and nuances we found. So, we brought Dr. Amy Valent https://www.ohsu.edu/providers/amy-valent-do of Oregon Health and Science University onto the show to break down the latest on what’s known about how these drugs affect fertility and pregnancy. Interested in more health news? Email us your question at [email protected] mailto:[email protected]. Support public media with NPR+ and enjoy perks for over 25 podcasts like this one. This show’s perks include sponsor-free listening. Learn more at plus.npr.org http://plus.npr.org/. See pcm.adswizz.com https://pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences. NPR Privacy Policy https://www.npr.org/about-npr/179878450/privacy-policy

Transcript

0:00
12:10

2,212 words · 7 speakers

Speaker names marked are inferred from speaking time and the show’s known hosts — they are not voice-verified.

Topics

  • GLP-1s
  • GLP-1 drugs
  • Ozempic
  • PMOS
  • Monjaro
  • Zepbound
  • American College of Obstetricians and Gynecologists
  • trisepotide
  • Oregon Health and Science University
  • PCOS

Page updated · transcript and summary are machine-generated